Breaking News
9 hours ago
Simantini Singh Deo
Commit Biologics Appoints Thomas L. F. Montgomery Andresen, Ph.D., As CEO As Company Prepares To Enter Clinical Development Following €21.5M Seed Backing From Novo Holdings
Simantini Singh Deo
Clearmind Medicine Inc. begins third cohort enrollment for CMND-100 trial targeting Alcohol Use Disorder.
Simantini Singh Deo
Bavarian Nordic A/S and Serum Institute of India Pvt. Ltd. expand partnership to scale manufacturing of the CHIKV VLP chikungunya vaccine.
Simantini Singh Deo
Quoin Pharmaceuticals Receives FDA Fast Track Designation For QRX003 Lotion To Advance Treatment For Netherton Syndrome
Simantini Singh Deo